A comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis

Front Endocrinol (Lausanne). 2024 Dec 20:15:1461754. doi: 10.3389/fendo.2024.1461754. eCollection 2024.

Abstract

Objectives: The study will evaluate the effectiveness and safety of finerenone in patients diagnosed with diabetic kidney disease (DKD).

Methods: Various databases including PubMed, Sinomed, Web of Science, Embase, Clinical Trials, and Cochrane Library were systematically reviewed for pertinent studies published from the beginning to February 2024.This meta-analysis utilized RevMan 5.3 and Stata 15.1.

Results: The analysis of 4 randomized controlled trials involving 13,943 participants found that finerenone treatment significantly decreased the urine albumin-to-creatinine ratio compared to placebo. Additionally, the risk of COVID-19, cardiovascular events, and estimated glomerular filtration rate(eGFR) reduction of at least 40% were all significantly lower in the finerenone treatment group. However, the finerenone group did experience higher baseline increases in serum potassium levels. The meta-analysis revealed that there was no variation in the likelihood of general negative outcomes (RR 1.00, 95% CI 0.98, 1.01, I2 = 0%) and the occurrence of cancers (RR 0.99, 95% CI 0.83, 1.18,I2 = 0%) among the two categories.

Conclusion: Our study demonstrates that finerenone has the potential to lower the chances of end-stage kidney disease, renal failure and cardiovascular mortality in individuals with diabetic kidney disease. It is important to monitor for hyperkalemia risk. The administration of finelidone among individuals with diabetic kidney disease may potentially mitigate the susceptibility to contracting COVID-19.

Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024536612.

Keywords: COVID-19; diabetic kidney disease; finerenone; malignancy; meta-analysis; renal function.

Publication types

  • Systematic Review
  • Meta-Analysis

MeSH terms

  • COVID-19 / complications
  • Diabetic Nephropathies* / drug therapy
  • Glomerular Filtration Rate
  • Humans
  • Mineralocorticoid Receptor Antagonists / adverse effects
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Naphthyridines / adverse effects
  • Naphthyridines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • finerenone
  • Naphthyridines
  • Mineralocorticoid Receptor Antagonists

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China(82170712); the Shenzhen Key Medical Discipline Construction Fund(SZXK009);the Sanming Project of Medicine in Shenzhen(SZSM202211013)and the Shenzhen Second People’s Hospital Clinical Research Fund of Guangdong Province High-level Hospital Construction Project (Grant No. 20203357012).